1. Home
  2. VERO vs DRMA Comparison

VERO vs DRMA Comparison

Compare VERO & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Venus Concept Inc.

VERO

Venus Concept Inc.

HOLD

Current Price

$1.14

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERO
DRMA
Founded
N/A
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VERO
DRMA
Price
$1.14
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
17.7M
1.9M
Earning Date
11-13-2025
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,876,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$1.55
52 Week High
$14.50
$23.70

Technical Indicators

Market Signals
Indicator
VERO
DRMA
Relative Strength Index (RSI) 44.93 38.10
Support Level $1.24 $1.73
Resistance Level $1.44 $1.95
Average True Range (ATR) 0.30 0.47
MACD -0.11 -0.08
Stochastic Oscillator 1.88 1.25

Price Performance

Historical Comparison
VERO
DRMA

About VERO Venus Concept Inc.

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: